Cencora — May 6, 2026 release
Fiscal 2026 second-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001140859-26-000018
Showing in the filing
International Healthcare Solutions Segment (2)(3) - Adjusted operating income
“5% to 8% growth”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 17
Repurchase in Shares for FY2026
“$1 Billion”
Revenue for FY2026
“4% to 6% growth”
U.S. Healthcare Solutions Segment Revenue for FY2026
“4% to 6% growth”
International Healthcare Solutions Segment R… for FY2026
“8% to 10% growth”
Other Revenue for FY2026
“1% to 5% growth”
Other (2) for FY2026
“1% to 5% growth”
Adjusted operating income for FY2026
“12% to 14% growth”
U.S. Healthcare Solutions Segment (2) - Adju… for FY2026
“14% to 16% growth”
International Healthcare Solutions Segment (… for FY2026
“5% to 8% growth”
Adjusted diluted earnings per share for FY2026
“$17.65 to $17.90”
Adjusted Diluted EPS for FY2026
“$17.65 to $17.90”
Net interest expense for FY2026
“~$485M”
Adjusted effective tax rate for FY2026
“~20%”
Diluted weighted average shares outstanding for FY2026
“Under 195.5M”
Adjusted free cash flow for FY2026
“~$3.0B”
Capital expenditures for FY2026
“~$900M”
Quarterly cash dividend for FY2026
“$0.60 per common share”
Exhibit 99.1 · the passage around this item
… earlier in the release
Healthcare Solutions Segment (2) 4% to 6% growth $285.0B International Healthcare Solutions Segment (2)(3) 8% to 10% growth $28.3B Other (2) 1% to 5% growth $8.2B Adjusted operating income 12% to 14% growth $4.2B U.S. Healthcare Solutions Segment (2) 14% to 16% growth $3.3B International Healthcare Solutions Segment (2)(3) 5% to 8% growth $588M Other (2) High-single digit growth $352M Adjusted diluted earnings per share $17.65 to $17.90 $16.00 Net interest expense ~$485M $292M Adjusted effective tax rate ~20% 20.6% Diluted weighted average shares outstanding Under 195.5M 195.2M Adjusted free cash flow ~$3.0B $3.0B Capital expenditures ~$900M $668M (1) Bolded figures indicate updates to guidance metrics. (2) For further detail on fiscal 2025 revised reportable segment information, please reference Exhibit 99.2 to the Company’s Current Report on Form 8-K dated November 5, 2025. 4 (3) As reported guidance. For additional details regarding updated guidance expectations on a constant currency basis, please refer to our slide presentation for investors posted on the Company’s website at investor.cencora.com. Dividend Declaration The Company’s Board of Directors declared a quarterly cash dividend of $0.60 per common share, payable June 1, 2026, to stockholders of record at the close of business on May 15, 2026. Conference Call & Slide Presentation The Company will host a conference call to discuss its operating results at 8:30 a.m. ET on May 6, 2026. A slide presentation for investors has also been posted on the Compa
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.